Stocktoria

Summit Therapeutics Inc. SMMT

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2004-10-14

Summit Therapeutics Inc. statistics & valuation

Market cap$10.9B
P / B16.5×
Return on equity-163.9%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
2019202020212022202320242025
Operating margin (%)
-3697.60% -6185.20% -4764.30% -10225.40% 2019202020212022202320242025
Return on equity (%)
-36.90% -66.30% -106.40% -62.20% -791.50% -56.90% -163.90% 2019202020212022202320242025
Shares outstanding
335.9M 82.6M 131.7M 211.1M 701.7M 737.6M 775.4M 2019202020212022202320242025
Net debt ($)
2019202020212022202320242025
Share buybacks ($)
2019202020212022202320242025
Return on assets (%)
-30.30% -51.40% -78.20% -11.90% -303.00% -50.80% -143.70% 2019202020212022202320242025
Free cash flow margin (%)
-2821.30% -5643.30% -4029.50% -5986.70% 2019202020212022202320242025
Debt / equity (×)
2019202020212022202320242025
EPS ($)
-$0.89 -$0.76 -$0.67 -$0.41 -$0.99 -$0.31 -$1.44 2019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Operating margin———-10225.4%-4764.3%-6185.2%-3697.6%
Net margin———-11174.8%-4897.8%-6127.6%-3920.2%
FCF margin———-5986.7%-4029.5%-5643.3%-2821.3%
Return on assets-143.7%-50.8%-303.0%-11.9%-78.2%-51.4%-30.3%
Return on equity-163.9%-56.9%-791.5%-62.2%-106.4%-66.3%-36.9%
Current ratio9.8710.159.3016.933.804.415.78

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.